NOTE:
Unless noted otherwise, all medical/health advice has been given by non-medically qualified personnel.
All advice given on this site is designed to support and not replace any advice given by your personal physician.
If you have questions or concerns about individual health matters or the management of your diabetes, please consult your diabetes care team.
Seared tuna with butter beans and roasted tomatoes

Preheat the oven to 180ºC / 350ºF / gas mark 4. Mix together the cumin, coriander seeds and chilli flakes, press into both sides of the tuna and set aside for 30 minutes to allow the flavours to develop. Meanwhile, heat the oil in a small pan and fry the onion and garlic for 2-3 minutes. Transfer to an ovenproof dish with the butter beans and tomatoes, place in the oven for 30 minutes until the tomatoes begin to char. Heat a griddle pan until smoking and sear the tuna for about 1 m ...

See full recipe & ingredients

Site Update - Aug 2012
25 Jul 2012
Due to the upcoming re-launch and re-branding of the group, the site is being operated as a separate ... Read more
South Sefton Diabetes Group Update - Aug 2012
25 Jul 2012
Due to a decrease in attendance at the group meetings, the Chairman has requested a re-launch from D ... Read more
Recipe of the day
25 Jul 2012
Each day, a new recipe from our database will be selected for display on the index page. It will sh ... Read more
For more news posts, please visit our news section

Diabetes.co.uk related article links
Show Hide
Can insulin make people with diabetes obese
A new study has found evidence to suggest that high levels of insulin could contribute to the risk of obesity in people with type 2 diabetes. The research published in the journal Proceedings of the National Academy of Sciences showed that insulin treatment can trigger certain bodily functions in mice that cause them to become obese. Scientists at the University of Texas Southwestern Medical Center conducted their study on mice who had been bred to lack certain receptors that respond to the hormone glucagon. "We found that mice lacking the receptor for glucagon cannot get fat unless they are given the high levels of insulin found in mice (and humans) that have type 2 diabetes," commented Dr. Michael Roth, Professor of Biochemistry at UT Southwestern and a member of the university's Touchstone Diabetes Center. In people without type 2 diabetes, insulin is used up transferring glucose from the bloodstream into the cells, but in those with the metabolic disorder, poor insulin sensitivity or insulin resistance can lead to high blood insulin levels - a state called hyperinsulinemia. This high concentration can also be caused by intensive insulin treatment. The researchers warned that if the effect on the mice is also apparent in humans, doctors will have to take on extra considerations before recommending insulin therapy for already overweight patients. The extra insulin in the blood could be aggravating obesity and therefore diabetes. Based on their findings, the researchers suggested that insulin treatment for type 2 diabetics should be replaced with greater control over diet and with treatments that focus on glucagon control instead. Instead of focusing on insulin, there is apparently potential to affect this balance, and therefore treat diabetes, by changing glucagon levels, which should prevent the weight gaining effects of hyperinsulinemia that the researchers observed.
Takeda fails to overturn USD9 billion award for Actos cancer cover up
Takeda, manufacturers of the type 2 diabetes drug, Actos, have failed to overturn the award of $9 billion for covering up risks of bladder cancer associated with the drug. Takeda and marketing partner Lilly were charged with $9 billion punitive charges in April this year after the companies were found to be guilty of failing to notify patients, doctors and regulatory authorities of risks associated with the drug. Whilst Takeda have failed to overturn the decision, it intends to launch a separate appeal. The case of Terrence Allen vs Takeda showed that Takeda had been aware of possible increased risks of bladder cancer years before it included a warning of the risks. Furthermore, the case revealed that Takeda had destroyed thousands of emails and documents related to the cancer risks prior to the trial. Takeda has recently completed a 10 year epidemiology study showing no statistically significant increased risk of bladder cancer associated with using the drug. At 5 years, the study had shown significantly increased risks of bladder cancer in people taking the medication for over 2 years. Marketing partner Eli Lilly, which were charged with $3 billion out of the $9 billion total, has previously reported that it should be indemnified by Takeda under the terms of their deal, which would mean Takeda would be responsible for the $9 billion total.
NICE calls for more evidence on type 2 diabetes drug Jardiance
The National Institute for Health and Care Excellence (NICE) has said it is "minded not to recommend" the new diabetes drug treatment, Jardiance (empagliflozin), until it has more information from the drug's manufacturer. The new medication from Boehringer Ingelheim was yesterday rolled out across pharmacies in the U.S. as a prescription medication for adult patients with type 2 diabetes after receiving FDA regulatory approval earlier this month. It also has a European marketing authorisation for the treatment of type 2 diabetes as both a monotherapy, in patients who are intolerant to metformin, and add-on combination therapy with other glucose-lowering agents including insulin when these, together with diet and exercise, do not provide adequate blood glucose control. But in new draft guidance, the UK's health watchdog NICE has called for more evidence from Boehringer Ingelheim on empagliflozin before it can be recommended for use on the NHS. This includes more information "to help it decide whether empagliflozin is a cost-effective use of NHS resources." Commenting on the draft guidance Professor Carole Longson, Director of the NICE Centre for Health Technology Evaluation, said: "NICE already recommends several treatments, alongside lifestyle and dietary advice, specifically for managing blood sugar levels in people with type 2 diabetes. Each has its advantages and disadvantages that affect how suitable they are. "New treatments, like empagliflozin, will help clinicians give people with type 2 diabetes the right treatment." She added that while there is "good evidence which shows that empagliflozin is clinically effective", more information is needed "to demonstrate that it is cost effective when compared with other treatments the NHS already provides."
US company crowdfunding to develop basal insulin patch
A start up company has launched a crowdfunding campaign to raise money to continue work on developing a basal insulin patch for treating diabetes. In an age where pain relief and nicotine patches are commonplace, it might seem a wonder why an insulin patch is yet to be available. The answer lays in the fact that insulin molecules are usually too large to pass through the skin. However, the technology developed by the company Prometheon tackles this issue. The Topicon DM basal basal insulin patch has a layer which, when applied to the skin, melts into a dermoadhesive gel that enhances the passage of insulin through the skin. The patch allows insulin to be delivered steadily over a period of hours matching the action of analogue basal insulin injections. Delivery of basal insulin by patch has potential for use in both type 1 and type 2 diabetes. As well as removing the need for needles, the patch has an additional advantage over injections in that, if blood glucose levels are becoming too low, the patch can be removed and a new patch applied when blood sugar levels have returned to safe levels. In addition to delivering insulin, the Topicon patch could also have wider uses in delivering other medications that would usually need to be injected and this includes other injectable medication for diabetes such as GLP-1 analogues (incretin mimetics). The company Prometheon has close links with the University of Florida. The company was founded in 2011 by former University of Florida researcher Stephen Hsu. Prometheon's attempts to raise money to develop the insulin patch, has hit an early set back. The company had intended to raise $1 million through crowdfunding by the 8th of September but have, to date, raised just over $10,000. The company will likely need to adopt a different means of funding for the project to get back on track.
Type 2 diabetes drug Empagliflozin launched in US
A new medication for treating type 2 diabetes called empagliflozin is now available at pharmacies across the USA following recent approval from the country's health regulatory body. The drug's manufacturers, Boehringer Ingelheim and Eli Lilly, announced in a statement that empagliflozin tablets are now available, under the brand name Jardiance, by prescription to adults with type 2 diabetes to help improve blood glucose control, in addition to diet and exercise. Approved by the U.S. Food and Drug Administration (FDA) at the start of August, empagliflozin is a once-daily sodium glucose co-transporter (SGLT2) inhibitor. Like other drugs in this class, it works in a unique way to lower blood sugar levels by blocking the reabsorption of glucose in the kidneys and promoting excretion of excess glucose in the urine. FDA approval of the drug was based on data from more than 10 multinational clinical trials involving over 13,000 adults with type 2 diabetes. The late-stage studies showed empagliflozin significantly lowered HbA1c after 24 weeks as a stand-alone treatment or in combination with metformin, sulfonylureas, insulin and pioglitazone (Actos). The results also showed modest reductions in both body weight and systolic blood pressure, keeping in line with other SGLT2 inhibitors which have also been shown to be effective for weight loss. Urinary tract infections and vaginal yeast infections were the most commonly reported adverse side effects among empagliflozin users, according to the statement, while hypoglycemia was a common reaction in patients also treated with a sulfonylurea or insulin. Empagliflozin was recommended for approval by the European Medicines Agency in April 2014 and launched in the UK on August 14.
Sulphonylureas linked with higher risk of heart disease in women
A study of nurses with diabetes in the US shows that long term use of sulphonylureas could increase the risk of coronary heart disease. Sulphonylureas are a widely prescribed class of drug for treating type 2 diabetes. The medication stimulates the pancreas to release more insulin. Coronary heart disease is a condition in which a waxy plaque builds up in the coronary arteries which feed the heart. Researchers from Harvard University in the United States studied 4,902 women with diabetes and no evidence of heart disease at the start of the study. The women studied were those who were part of the Nurses' Health Study. The average age of the women was 68 years old and the average duration of diabetes of 11 years at the start of the study. The medications that each of the women were taking for their diabetes was recorded at the start of the study and up to 10 years later, at the end of the study. Over the course of the study there were 191 cases of coronary heart disease and 148 cases of stroke amongst the nurse participants. The researchers found that the longer sulphonylureas were used, the higher the rates of coronary heart disease. In their analysis, the researchers took into account other factors that influence risk of heart disease such as age, diabetes duration, BMI, presence of diabetes complications and family history of cardiovascular disease. The increased risks of coronary heart disease for those that used sulphonylureas compared with those that did not were as follows: Use of sulphonylureas for 1 to 5 years: 24% increased risk Use of sulphonylureas for 6 to 10 years: 51% increased risk Use of sulphonylureas for over 10 years: 115% increased risk Whilst the researchers found an increased risk of coronary heart disease with sulphonylurea use, no increased risk of stroke was observed with the medication. The increased risk of coronary heart disease with sulphonylurea use may be explained by the fact that these medications increase the amount of insulin circulating in the blood. Higher levels of circulating insulin have been found to be associated with increased risk of heart disease in previous studies.
Team Novo Nordisk bringing diabetes cycling initiative to the UK
A team of diabetic cyclists are to race in the UK for the first time today as they continue their mission to inspire, educate and empower people affected by diabetes. Team Novo Nordisk is the first all-diabetes professional cycling team, with every member of the team living with type 1 diabetes. This means having to keep blood sugar levels under control whilst training and racing in one of the toughest endurance sports, at the highest level. Created in 2012, the unique team competes in major professional races around the world and their next challenge is to take part in the UK’s leading professional cycling race, The Tour of Britain. Split into nine stages, the cross-country race kicks off in Liverpool on Sunday 7th September and finishes a week later in London. By competing in The Tour of Britain, Team Novo Nordisk hope to continue inspiring the 3.2million people with diabetes in the UK by showing just what can be achieved with good diabetes management. Co-founder and CEO Phil Southerland, who has lived with type 1 diabetes his whole life, said: "When diagnosed with diabetes, many people think it means they won’t be able to live life the way they’d hoped. Team Novo Nordisk is racing to inspire people with diabetes to set and achieve their goals, whatever they may be, and show that the first step towards this is good diabetes control." Dr Rafael Castol, Team Novo Nordisk Medical Director, commented: "Good control can be achieved through diet and exercise, in combination with medication in many cases. "Stepping up levels of exercise doesn’t have to be off limits for people with diabetes, provided it is discussed and planned with the individual’s healthcare team." The Team Novo Nordisk sports initiative is part of the Danish pharmaceutical company's global Changing Diabetes campaign, which aims to improve health outcomes for people with diabetes by highlighting the need for earlier detection and better management of the disease.
Gestational diabetes linked with higher diabetes risk in obese children
Children that developed in the womb whilst their mothers had gestational diabetes were over 3 times more likely to develop glucose intolerance according to the results of a new clinical study. Gestational diabetes is a form of diabetes that develops during pregnancy, as a result of high levels of hormones produced by the placenta. Unlike most other types of diabetes, gestational diabetes is usually temporary, with high blood sugar levels reverting back to normal after the pregnancy. Gestational diabetes can occur in people of any weight, which is why gestational diabetes should be screened for in every pregnancy in the UK, but becomes more likely the more overweight you are. In the study carried out by researchers at the Yale University School of Medicine, 225 children and teenagers, between the age of 4 and 20 were selected for the study. The youths selected were obese but with normal glucose tolerance, as shown by an oral glucose tolerance test (OGTT). The youths were then monitored after 2.8 years for glucose intolerance. For the analysis, the researchers divided the youngsters into two groups, those whose mothers had gestational diabetes during their pregnancy and those whose mothers did not. 18% of the mothers had developed gestational diabetes during pregnancy and the other 82% did not. The results showed that there were significant differences between incidences of insulin resistance in the youngsters of mothers that had gestational diabetes and those that did not. Of the youngsters born to mothers that had gestational diabetes, 31% recorded glucose intolerance on the OGT test at around 3 years after the recruitment period. By comparison, of the youngsters born to mothers that did not have gestational diabetes, only 9% of them developed impaired glucose tolerance. The study shows that obese youngsters are more likely to develop insulin resistance (the cause of prediabetes and type 2 diabetes) than obese youngsters whose mothers did not develop gestational diabetes. More research will be needed to determine why this is the case. Factors that could be responsible include: gestational diabetes directly affecting the child's metabolism, genetic factors being passed on from mother to child, or lifestyle factors related to insulin resistance (such as certain dietary components and levels of activity) being shared by both mother and child.
Leicester diabetes clinics set for general hospital move
Hospital diabetes services in Leicester are to be relocated after it was announced that a diabetes outpatient department will open at Leicester General Hospital next month. The opening of the new department will see diabetes outpatient clinics currently held at Leicester Royal Infirmary move to the General, while all diabetes outpatient clinics that currently take place in portable buildings at the General will also relocate. Justin Dobson, operational manager for medicine at University Hospitals of Leicester NHS Trust, said: "By moving to the General, we are uniting our services. As a result, we hope to offer a better experience for our patients." Work has already started on renovating the home of the Ward 4 department in time for a mid-September launch. While the move takes place, the number of diabetes clinics will be a reduced during the week starting September 8, but normal service will resume when the first clinic in the new location opens its doors on September 15. The decision to move the outpatient clinics is part of plans at city hospitals to allow for the development of the emergency floor at Leicester Royal Infirmary.
Implanted islet cells for type 1 diabetes gets approval for human trials
The US Food and Drug Administration have approved human trials for a new technique of implanting insulin producing islet cells. The product that has received approval is called VC-01, with VC standing for 'virtual cure'. VC-01 involves a capsule, called the Encaptra drug delivery system, being implanted under the skin. Within the Encaptra system are stem cells, called PEC-01 cells, which have been programmed to develop into insulin producing islet cells. The Encaptra system has life changing properties for people with type 1 diabetes as it allows insulin to pass out of the capsule, nutrients such as glucose and oxygen to pass into the capsule to feed the living cells yet protects the cells from the immune attack of type 1 diabetes. The major problem in type 1 diabetes is that the immune system gets incorrectly programmed to attack insulin producing cells. The human clinical trials will therefore allow ViaCyte, the company that has developed the VC-01 system, to test how strongly the technique performs in humans with type 1 diabetes. ViaCyte has received an important boost this week, towards funding human trials, as the company has recently received $20 million (around 12 million) from the large pharmaceutical firm Johnson and Johnson. The new technology from ViaCyte also has the type 1 diabetes charity, the JDRF, to thank for help in funding earlier development work. The FDA approval means that the VC-01 product can begin phase I and phase II human clinical trials to test whether the islet cell encapsulation therapy is effective within humans.